News|Videos|May 8, 2026

5 Gastroenterology Headlines You Missed in April 2026

Catch up on new IBD drug trial data, regulatory actions, and updates in IBS in this April month in review.

April brought continued momentum in gastroenterology, with advances in inflammatory bowel disease (IBD) research, regulatory activity, and new discussions surrounding the long-term management of irritable bowel syndrome (IBS). From emerging next-generation biologics to evolving treatment strategies in ulcerative colitis and Crohn’s disease, the month highlighted both the pace of innovation in GI care and the ongoing need to address persistent gaps in patient outcomes.

Related to this article

November 6th, 2026

Saroglitazar Resolves MASH Without Fibrosis Worsening: EVIDENCES X

In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.

November 6th, 2026

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.

November 6th, 2026

Semaglutide Linked to Lower Liver Enzymes, Weight in Real-World MASH Data

Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.

November 6th, 2026

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.

November 6th, 2026

Triple Therapy More Than Doubles HBsAg Loss vs Peginterferon in HBV

Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.

November 6th, 2026

Fazirsiran Reduces Liver Z-AAT Burden in AATD Liver Disease

Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.

November 6th, 2026

Once-Monthly Efimosfermin Improves Fibrosis Markers in Phase 2 MASH Study

Once-monthly efimosfermin alfa reduced liver stiffness, ELF, and PRO-C3 through 52 weeks in MASH with F2–F4 fibrosis, including compensated cirrhosis.

2027 GOLD Report Updates: Changes in COPD Treatment, Biologics

November 6th, 2026

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Alvar Agustí, MD, previews key 2027 GOLD report changes, from initial COPD treatment and new biologic data to a GOLD Science Committee call to action.